Direct Biologics Granted FDA Approval of Third IND Application for the Use of ExoFlo in Mild-to-Moderate COVID-19 Infusion Therapy ...Middle East

AUSTIN, Texas, June 29, 2021 /PRNewswire/ -- Direct Biologics, a market-leading innovator and cGMP manufacturer of regenerative biologic products, announced today that the U.S. Food and Drug Administration (FDA) has approved the application for a Phase I/II trial under an Investigational...

Hence then, the article about direct biologics granted fda approval of third ind application for the use of exoflo in mild to moderate covid 19 infusion therapy was published today ( Tuesday 29/06/2021 - 11:45 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Direct Biologics Granted FDA Approval of Third IND Application for the Use of ExoFlo in Mild-to-Moderate COVID-19 Infusion Therapy )

Also on site :

• Here’s how 2025 killed old-school diplomacy
• The Board of Directors of SciBase resolves on a previously communicated rights issue of shares of approximately SEK 83 million
• 'Baylen Out Loud': Baylen Tries First Taste of Beer at British Pub & Her Response Is Totally Unexpected (Exclusive Clip)